LANCL2-Binding Small Molecules for Oral Anti-Inflammatory Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoimmune and chronic inflammatory diseases, such as inflammatory bowel disease, rheumatoid arthritis, and type 2 diabetes, are expensive and have significant side effects, while existing compounds targeting the LANCL2 pathway are not tailored to individual diseases and may not maximize efficacy.
Innovation Solution
Development of novel biologically active compounds that bind to the LANCL2 protein, specifically designed through medicinal chemistry approaches and validated using in silico, in vitro, and in vivo techniques, to treat autoimmune, chronic inflammatory, and metabolic diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-TNF antibodies are used to treat autoimmune diseases, then therapeutic effectiveness is improved, but cost and side effects increase
Solution Approach 1:
The patent changes the molecular parameters of the therapeutic agent by designing small molecule compounds with specific chemical structures (formula I) that target LANCL2, replacing the large protein-based anti-TNF antibodies. This parameter change enables oral administration, reduces cost, and minimizes side effects while maintaining therapeutic effectiveness through activation of the LANCL2 pathway.
Solution Approach 2:
The patent substitutes the mechanical injection system required for anti-TNF antibodies with an oral administration system. The small molecule compounds can be administered via oral tablets or capsules, eliminating the need for clinical visits, injections, and frequent monitoring, thereby reducing cost and improving patient convenience.
2Object-generated harmful factors
If existing LANCL2 pathway compounds are used, then inflammation reduction is achieved, but disease-specific efficacy is not optimized
Solution Approach 1:
The patent applies local quality by designing compounds with specific molecular structures (formula I) that are optimized for binding to LANCL2 in different tissue contexts. The compounds incorporate disease-relevant pharmacophores that enable targeted activation of LANCL2 in specific organs or tissues, such as the gut for IBD or pancreas for diabetes, thereby optimizing disease-specific efficacy while maintaining general anti-inflammatory activity.
3Ease of operation
If oral administration is implemented, then ease of use is improved, but compound stability and bioavailability must be maintained
Solution Approach 1:
The patent employs a disposable oral formulation approach where the small molecule compounds are designed for rapid absorption and metabolism. The compounds are formulated as oral tablets or capsules that dissolve in the gastrointestinal tract, releasing the active compound for quick binding to LANCL2 and subsequent metabolic clearance, eliminating the need for complex stability maintenance systems.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively reduce inflammation and increase insulin sensitivity, providing therapeutic benefits comparable to anti-TNF antibodies without side effects and are orally administered, offering a cost-effective alternative.
Implementation Method 1
Abscisic acid ('ABA') is one of the natural compounds found in the original screening process that binds to LANCL2
Data Source
AI summary
Provided are compounds that target the lanthionine synthetase C-like protein 2 pathway. The compounds can be used to treat a number of conditions, including infectious disease, autoimmune disease, diabetes, and a chronic inflammatory disease.